A Phase 3 interventional study of isatuximab SAR650984 and carfilzomib in Plasma Cell Myeloma, sponsored by Sanofi. Completed at 70 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Multiple Myeloma by Sanofi — 3 open to participants now, 8 under way, 3 of them phase 3. Multiple Myeloma · Sanofi.
Among the 39 studies in Multiple Myeloma by Sanofi, this one is the 5th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 26th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →3 of the 39 studies in Multiple Myeloma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Australia, Canada and 4 more countries
Ages 18+
Sanofi · Sites in United States, Australia, France and 6 more countries
Ages 18+
Sanofi · Sites in United States, Australia, Brazil and 14 more countries
Ages 18+
By country, each count listing its studies:
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 17 · Phase 3 7
First in 2002; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 302 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 56 across the 34 interventional studies, 423 across the 4 observational. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
3 of the studies in Multiple Myeloma by Sanofi that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT06356571SanofiA Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | 2027-04-01 |
| NCT04643002SanofiIsatuximab in Combination With Novel Agents in RRMM - Master Protocol | 2027-09-13 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies in Multiple Myeloma by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study it to compare the efficacity of isatuximab when combined to carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with multiple myeloma already treated with 1 to 3 prior lines of therapy.
The duration of the study for a patient will include a period for screening of up to 3 weeks. Patients will be treated until disease progression, unacceptable AE, or patient decision to stop the study treatment. After study treatment discontinuation, patients will have follow-up visits until the analysis of overall survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Isatuximab (intravenous) on day 1, 8, 15 and 22 of 1st cycle, then on day 1 and 15 of subsequent cycles in combination with carfilzomib (intravenous) on day 1, 2, 8, 9, 15 and 16 + dexamethasone (intravenous or by mouth \[po\]) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle.
Drug: isatuximab SAR650984 · Drug: carfilzomib · Drug: dexamethasone
Carfilzomib (intravenous) on day 1, 2, 8, 9, 15, 16 + dexamethasone (intravenous or po) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle.
Drug: carfilzomib · Drug: dexamethasone
Pharmaceutical form: solution for infusion Route of administration: intravenous
Also known as: Sarclisa
Pharmaceutical form: solution for infusion Route of administration: intravenous
Also known as: Kyprolis
Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous
Progression Free Survival (PFS) As Determined by Independent Response Committee (IRC): Primary Analysis
Time (in months) from randomization to date of 1st documentation of progressive disease (PD)/date of death from any cause, whichever comes 1st. If PD \& death are not observed before cut-off date/date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment not showing PD performed prior to initiation of further anti-myeloma treatment/cut-off date, whichever comes 1st. PD(IMWG criteria):any 1 of following:Increase(inc) of \>=25% in serum M-component from nadir; serum M component inc \>=1 g/dL in 2 consecutive assessment, if starting M component \>=5 g/dL; and/or inc of \>=25% in urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc \>=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion if \>1 lesion/ \>=50% increase in longest diameter of previous soft tissue extramedullary disease lesion \>1 cm in short axis. Estimated by Kaplan-Meier method.
Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (median duration of follow-up was 20.73 months)
Progression Free Survival as Determined by Independent Response Committee: [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Primary Analysis
Time (in months) from randomization to date of 1st PD documentation/death date, whichever is 1st. If PD \& death not observed before cut-off date/date of further anti-myeloma treatment initiation, PFS censored at date of last valid disease assessment not showing PD performed prior to initiation of further anti-myeloma treatment/cut-off date, whichever was 1st. Progression/deaths occurring \>8 weeks after last disease assessment censored at earliest date of last disease assessment without evidence of progression before initiation of new anti-myeloma treatment \& cut-off date. PD (IMWG criteria): meeting any 1: Inc \>=25% in Serum M-component from nadir; serum M component inc \>=1 g/dL in 2 consecutive assessment, if starting M component \>=5 g/dL; and/or inc \>=25% in Urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc \>=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion \>1 cm short axis.
Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
Progression Free Survival as Determined by Independent Response Committee: Final Analysis
PFS: time (in months) from randomization to date of first documentation of PD or date of death from any cause, whichever comes first. If PD and death are not observed before analysis cut-off date or date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment or analysis cut-off date, whichever comes first. PD as per IMWG criteria: any 1 of following: Inc of \>=25% in Serum M-component from nadir; serum M component increase \>=1 g/dL in 2 consecutive assessment, if starting M component was \>=5 g/dL; and/or inc of \>=25% in Urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc \>=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion if \>1 lesion/ \>=50% inc in longest diameter of previous soft tissue extramedullary disease lesion \>1 cm in short axis. PFS estimated by Kaplan-Meier method.
Time frame: From randomization until the final analysis data cut-off date of 14 January 2022 (the median duration of follow-up was 43.96 months)
Progression Free Survival as Determined by Independent Response Committee [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Final Analysis
Time (in months) from randomization to date of 1st documentation of PD/date of death from any cause, whichever comes 1st. If PD \& death are not observed before cut-off date/date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment not showing PD/cut-off date, whichever comes 1st. Progressions/deaths occurring \>8 weeks after last disease assessment were censored at earliest date of last valid disease assessment not showing PD before initiation of further anti-myeloma treatment \& cut-off date. PD (per IMWG criteria): meeting any 1 criteria: Inc of \>=25% in serum M-component from nadir; serum M component inc \>=1 g/dL in 2 consecutive assessment, if starting M component was \>=5 g/dL; and/or inc of \>=25% in urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc \>=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion \>1 cm in short axis.
Time frame: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
Percentage of Participants With Overall Response (OR) as Determined by Independent Response Committee: Primary Analysis
OR: participants with sCR, CR, VGPR \& partial response (PR) as best overall response assessed by IRC using IMWG response criteria (from start of treatment until disease progression, death, initiation of further anti-myeloma treatment/cutoff date, whichever occurs 1st). sCR: negative immunofixation on serum \& urine, disappearance of soft tissue plasmacytoma, \<5% plasma cells in bone marrow aspirate (BMA) + normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum \& urine, disappearance of soft tissue plasmacytoma, \<5% plasma cells in BMA. VGPR: serum \& urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein + urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. PR:\>=50% reduction of serum M-protein \& decrease in 24h urinary M-protein by \>=90%/\<200mg/24h, if present at baseline,\>=50% decrease in SPD of soft tissue plasmacytoma.
Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
Percentage of Participants With Very Good Partial Response (VGPR) or Better as Determined by Independent Response Committee: Primary Analysis
VGPR or better: defined as participants with sCR, CR and VGPR as the best overall response (defined as best response from start of treatment until disease progression, death, initiation of further anti-myeloma treatment or cut-off date whichever occurs first) as per IRC. As per IMWG response criteria: sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in BMAs plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in BMAs. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein plus urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma.
Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
Percentage of Participants With VGPR or Better With Minimal Residual Disease (MRD) Negativity: Primary Analysis
Percentage of participants with sCR, CR and VGPR for whom MRD assessed by sequencing was negative at any time after first dose of study treatment. MRD was assessed centrally by next-generation sequencing in bone marrow aspiration samples from participants who achieve VGPR or better, to determine depth of response at molecular level. VGPR or better: percentage of participants with sCR, CR and VGPR. sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in BMAs plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in BMAs. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein plus urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma.
Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
Percentage of Participants With VGPR or Better With Minimal Residual Disease (MRD) Negativity: Final Analysis
Percentage of participants with sCR, CR and VGPR for whom MRD assessed by sequencing was negative at any time after first dose of study treatment. MRD was assessed centrally by next-generation sequencing in BM aspiration samples from participants who achieve VGPR or better, to determine depth of response at molecular level. VGPR or better: percentage of participants with sCR, CR and VGPR. sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates plus normal FLC ratio, absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein plus urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma.
Time frame: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
Percentage of Participants With Complete Response (CR) as Per Independent Response Committee: Final Analysis
Complete response was defined as the participants with sCR and CR. IMWG response criteria for sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates plus normal free light chain (FLC) ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates. Complete response at the time of the final analysis was assessed with hydrashift isatuximab immunofixation electrophoresis (IFE) assay, which separated immunoglobulin G (IgG) isatuximab from IgG M protein.
Time frame: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
Percentage of Participants With Complete Response With MRD Negativity: Final Analysis
MRD negativity was defined as the percentage of participants for whom MRD was negative by next-generation sequencing at any timepoint after first dose of study treatment. Threshold for negativity is 10\^-5. MRD status in a participant was negative if at least one result of the assessment was negative in the participant otherwise MRD was considered as positive (MRD status reported as positive, missing or unevaluable). CR: participants with sCR and CR. IMWG response criteria for sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates. Complete response at the time of the final analysis was assessed with Hydrashift isatuximab IFE assay, which separated IgG isatuximab from IgG M protein.
Time frame: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
Overall Survival (OS)
Overall survival, defined as the time from the date of randomization to death from any cause. The data reported is based on cut-off date of 7 Feb 2023.
Time frame: From randomization until the final analysis data cut-off date of 7 Feb 2023 (the median duration of follow-up was 56.61 months)
Duration of Response (DOR): Primary Analysis
DOR: time (in months) from date of 1st IRC determined response for participants achieving PR/better to date of 1st documented PD determined by IRC/death, whichever happens 1st. If disease progression/death before analysis cut-off date was not observed, DOR was censored at date of last valid disease assessment performed prior to initiation of further anti-myeloma treatment/data cut-off date, whichever was 1st. PD (IMWG criteria): inc of \>=25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute inc must be \>=0.5 g/dL), serum M-protein inc \>=1g/dL if lowest M component was \>=5g/dL; urine M-component (absolute inc must be \>=200mg/24 hour),appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>=50% inc in the longest diameter of previous lesion \>1 cm in short axis. PR: \>=50% reduction of serum M-protein \& reduction in 24h urinary M-protein by \>=90%/\<200mg/24 h. Estimated by Kaplan Meier method.
Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
Time to Progression (TTP): Primary Analysis
TTP was defined as time in months from randomization to the date of first documentation of PD (as determined by the IRC). If progression was not observed before the analysis cut-off date or the date of initiation of further anti-myeloma treatment, TTP was censored at the date of the last valid disease assessment not showing disease progression performed prior to initiation of a further anti-myeloma treatment (if any) or the analysis cut-off date, whichever comes first. As per IMWG criteria, PD was defined for participants with inc of \>= 25% from lowest confirmed value in any one of the following criteria: serum M-protein (the absolute inc must be \>= 0.5 g/dL), serum M-protein inc \>=1 g/dL if the lowest M component was \>=5 g/dL; urine M-component (the absolute inc must be \>=200 mg/24hour), appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>=50% inc in the longest diameter of a previous lesion \>1 centimeter in short axis.
Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
Time to First Response: Primary Analysis
Time to first response was defined as the time (in months) from randomization to the date of first IRC determined response (PR or better) that is subsequently confirmed. In the absence of response, participants were censored at the earliest of the date of the last valid disease assessment before disease progression or death, the date of the last valid disease assessment before initiation of a further anti-myeloma treatment (if any) or the analysis cut-off date, whichever comes first. PR per IMWG criteria was defined as \>=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>=90% or to \<200 mg/24 h. In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required.
Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
Time to Best Response: Primary Analysis
Time to best response was defined as time (in months) from randomization to the date of first occurrence of IRC determined as best overall response (PR or better) that is subsequently confirmed. In absence of response, participants were censored at earliest date of last valid disease assessment before disease progression/death, date of last valid disease assessment before initiation of further anti-myeloma treatment (if any)/ analysis cut-off date, whichever was 1st. PR (IMWG criteria) was defined as \>=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>=90% or to \<200 mg/24 h. In addition to above listed criteria, if present at baseline, a \>=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required. Best Overall Response was defined as the best response, using the IRC's assessment of response, from start of treatment until disease progression, death, initiation of further anti-myeloma treatment or cut-off date, whichever occurs 1st.
Time frame: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
Second Progression Free Survival (PFS2): Final Analysis - Data Cut-off Date of 14 Jan 2022
PFS2 defined as time (in months) from date of randomization to date of 1st documentation of PD (as assessed by investigator) after initiation of further anti-myeloma treatment /death from any cause, whichever comes 1st. Participants alive without progression after initiation of further anti-myeloma treatment before analysis cut-off date, PFS2 censored at date of last follow-up visit not showing disease progression after initiation of further anti-myeloma treatment /analysis cut-off date, whichever comes 1st. As per IMWG criteria, PD: defined for participants with increase of \>= 25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute increase must be \>= 0.5 g/dL), serum M-protein increase \>=1 g/dL if lowest M component was \>=5 g/dL; urine M-component (absolute increase must be \>=200 mg/24hour), appearance of new lesion(s), \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter short axis.
Time frame: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
Second Progression Free Survival (PFS2): Overal Survival Analysis - Data Cut-off Date of 07 Feb 2023
PFS2 defined as time (in months) from date of randomization to date of 1st documentation of PD (as assessed by investigator) after initiation of further anti-myeloma treatment /death from any cause, whichever comes 1st. Participants alive without progression after initiation of further anti-myeloma treatment before analysis cut-off date, PFS2 censored at date of last follow-up visit not showing disease progression after initiation of further anti-myeloma treatment /analysis cut-off date, whichever comes 1st. As per IMWG criteria, PD: defined for participants with increase of \>= 25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute increase must be \>= 0.5 g/dL), serum M-protein increase \>=1 g/dL if lowest M component was \>=5 g/dL; urine M-component (absolute increase must be \>=200 mg/24hour), appearance of new lesion(s), \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter short axis.
Time frame: From randomization until the overal survival analysis data cut-off date of 07 Feb 2023 (the median duration of follow-up was 56.61 months)
Number of Participants With Renal Response (RR): Primary Analysis
RR comprises of complete RR (CR renal), partial RR (PR renal) \& minor RR (MR renal). CR renal was defined as an improvement in estimated glomerular filtration rate (eGFR) from \<50 mL/min/1.73m\^2 at Baseline to \>=60 mL/min/1.73m\^2 in at least 1 assessment during the treatment period (time from first dose of study treatment up to 30 days after last dose of study treatment); PR renal was defined as improvement in eGFR from \<15 mL/min/1.73m\^2 at baseline to at least 1 assessment in the range of 30 to 60 mL/min/1.73m\^2 during the on-treatment-period and MR renal was defined as an improvement in eGFR from \<15 mL/min/1.73m\^2 at Baseline to at least 1 assessment in the range of 15 to 30 mL/min/1.73m\^2 during the on-treatment-period or from 15 to 30 mL/min/1.73m\^2 at Baseline to at least 1 assessment in the range of 30 to 60 mL/min/1.73m\^2 during the on-treatment-period.
Time frame: From the first dose of study treatment to 30 days following the last administration of study treatment (maximum duration: up to 114 weeks)
Health Related Quality of Life (HRQL): Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 30 Items (EORTC QLQ-C30): Global Health Status Score at Specified Timepoints
EORTC QLQ-C30 is a cancer-specific instrument that contains 30 items \& provides multidimensional assessment of HRQL. EORTC QLQ-C30 includes global health status/quality of life (GHS/QOL), functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 are 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale \& are 7-point scale (1/Very Poor to 7/Excellent). GHS total score is calculated as (\[{Q29+Q30}/2\]-1)/6\*100. Answers are converted into grading scale, with values between 0 (worse outcome) to100 (best outcome). High score represents a favorable outcome with best quality of life for participant. Results reported for primary analysis with data cut-off date 7-Feb-2020.
Time frame: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
HRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Disease Symptoms Domain Score at Specified Timepoints: Primary Analysis
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. Disease symptoms domain is one of the four domain scores. Disease symptoms domain consist of 6 questions and the score uses 4-point scale (1 'Not at All' to 4 'Very Much'). Disease Symptoms Domain Score is calculated as (\[{Q31+Q32+Q33+Q34+Q35+Q36}/6\]-1)/3\*100. Scores are averaged, and transformed to 0-100 scale, where higher scores = more symptoms and lower HRQL.
Time frame: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
HRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Side Effects of Treatment at Specified Timepoints: Primary Analysis
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. Side effects of treatment domain is one of the four domain scores. Side effects of treatment domain consists of 10 questions and the score uses a 4-point scale (1 'Not at All' to 4 'Very Much'). Side Effects of Treatment Score (MYSE) is calculated as (\[{Q37+Q38+Q39+Q40+Q41+Q42+Q43+Q44+Q45+Q46}/10\]-1)/3\*100. Scores are averaged, and transformed to 0-100 scale, where higher scores = more side effects and lower HRQL and lower scores = less side effects and better HRQL.
Time frame: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
HRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Body Image Score at Specified Timepoints: Primary Analysis
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. It consists of one question and scores are based on the 4-point Likert scale ranging from "Not at all" to "Very much". Body image score is calculated as: (1 - \[Q47-1\]/3)\*100. Scores are averaged, and transformed to scale ranging from 0 to 100. A higher score represents a better quality of life.
Time frame: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
HRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Future Perspective at Specified Timepoints: Primary Analysis
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. It consists of three questions and the scores are based on the 4-point Likert scale ranging from "Not at all" to "Very much". Future Perspective score is calculated as (1 - (\[{Q48+Q49+Q50}/3\] -1)/3)\*100. Scores are averaged and transformed to scale ranging from 0 to 100. A higher score represents a better quality of life.
Time frame: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
HRQL: Change From Baseline in European Quality of Life Group Questionnaire With 5 Dimensions and 5 Levels Per Dimension (EQ-5D-5L): Health State Utility Index Value at Specified Timepoints: Primary Analysis
The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health utility and consist in 2 sections a descriptive system comprising 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and Visual Analog Scale (VAS). Each dimension has a 5-level response: no problems, slight problems, moderate problems, severe problems, and extreme problems. Response options are measured with a 5-point Likert scale. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state and lower score indicate worse health state.
Time frame: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
HRQL: Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Score: Visual Analogic Scale (VAS) at Specified Timepoints: Primary Analysis
The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health utility and consist of 2 sections; descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a VAS. The VAS records the respondent's self-rated health on a 20 centimeter (cm) vertical VAS; the scale went from 0 (worst imaginable health state) to 100 (best imaginable health state). This information can be used as a quantitative measure of health as judged by the individual respondents.
Time frame: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
Pharmacokinetics: Plasma Concentration at End of Infusion (Ceoi) of Isatuximab: Primary Analysis
Ceoi is the plasma concentration observed at the end of intravenous infusion.
Time frame: End of infusion on Cycle 1 Day 1 and Cycle 1 Day 15; Cycle 2 Day 1
Pharmacokinetics: Plasma Concentration of Isatuximab at Ctrough: Primary Analysis
Ctrough was the plasma concentration observed just before treatment administration during repeated dosing.
Time frame: Pre-infusion on Cycle 1 Day 1, Day 8, Day 15 and Day 22, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1, Cycle 8 Day 1, Cycle 9 Day 1 and Cycle 10 Day 1
Pharmacokinetics: Maximum Observed Concentration (Cmax) of Carfilzomib: Primary Analysis
Cmax was defined as the maximum concentration observed after the first infusion calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
Time frame: Cycle 1: pre-dose (0 hour), 30 minutes (min), 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Pharmacokinetics: Clast of Carfilzomib: Primary Analysis
Clast was defined as the last concentration observed above the lower limit of quantification.
Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Pharmacokinetics: Tmax of Carfilzomib: Primary Analysis
Tmax was defined as the time to reach Cmax, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Pharmacokinetics: Tlast of Carfilzomib: Primary Analysis
Tlast was defined as the time of last concentration observed above the lower limit of quantification, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Pharmacokinetics: Area Under the Plasma Concentration Time Curve (AUC) of Carfilzomib: Primary Analysis
AUC was defined as area under the plasma concentration-time curve extrapolated to infinity according to the equation: AUC= AUClast + Clast/λz. AUC was calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Pharmacokinetics: Area Under the Plasma Concentration Time Curve From Time 0 to Last Quantifiable Concentration (AUClast) of Carfilzomib: Primary Analysis
AUClast was defined as area under the plasma concentration versus time curve calculated from time 0 to last quantifiable concentration. AUClast was calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Pharmacokinetics: Percentage of Extrapolation of AUC (AUCext) of Carfilzomib: Primary Analysis
AUCext was defined as the percentage of the extrapolation of AUC, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Pharmacokinetics: Terminal Half-life (t1/2z) of Carfilzomib: Primary Analysis
T1/2 was defined as the time required for the concentration of the drug to reach half of its original value, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Pharmacokinetics: Clearance at Steady State (CLss) of Carfilzomib: Primary Analysis
CLss was defined as a quantitative measure of the rate at which a drug substance is removed from the body at steady state, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Pharmacokinetics: Volume of Distribution at Steady State (Vss) of Carfilzomib: Primary Analysis
Volume of Distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss is the apparent volume of distribution at steady-state, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
Time frame: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
Number of Participants With Anti-Drug Antibodies (ADA): Primary Analysis
ADA were categorized as: pre-existing, treatment induced, and treatment boosted response. Pre-existing ADA was defined as ADA that were present in samples drawn during the pretreatment period (i.e., before the first isatuximab administration). Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA, including participants without pretreatment samples. Treatment boosted ADA was defined as pre-existing ADA with an increase in titer during the ADA on-study observation period.
Time frame: From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: 111 weeks)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs): LPLV Analysis
Adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAEs were defined as AEs that developed, worsened, or became serious during the treatment period (time from the first dose of study treatments up to 30 days after last dose of study treatments). An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability / incapacity, was a congenital anomaly/birth defect, was a medically important event.
Time frame: From first dose of study treatment administration (Day 1) up to 30 days post last dose of study treatment administration, up to 349 weeks for Kd arm and 356 weeks for IKd arm (maximum duration of treatment exposure)
Study was conducted at 69 active centers in 16 countries. A total of 341 participants were screened between 25 October 2017 and 21 March 2019, of which 39 participants were screen failure due to not meeting eligibility criteria. Randomization was stratified by number of prior lines (1 versus \>1) \& revised international staging system (R-ISS) I or II versus III versus not classified. Reason for not completed = Reason for definitive treatment discontinuation.
| Milestone | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Started | 123 | 179 |
| Treated | 122 | 177 |
| Completed | 0 | 0 |
| Not completed | 123 | 179 |
| Withdrew: Adverse event | 24 | 29 |
| Withdrew: Progressive disease | 68 | 86 |
| Withdrew: Withdrawal by subject | 18 | 21 |
| Withdrew: Treatment extension study | 1 | 24 |
| Withdrew: Randomized and not treated | 1 | 2 |
| Withdrew: Study discontinuation | 1 | 5 |
| Withdrew: Others | 10 | 12 |
OR: participants with sCR, CR, VGPR \& partial response (PR) as best overall response assessed by IRC using IMWG response criteria (from start of treatment until disease progression, death, initiation of further anti-myeloma treatment/cutoff date, whichever occurs 1st). sCR: negative immunofixation on serum \& urine, disappearance of soft tissue plasmacytoma, \<5% plasma cells in bone marrow aspirate (BMA) + normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum \& urine, disappearance of soft tissue plasmacytoma, \<5% plasma cells in BMA. VGPR: serum \& urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein + urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. PR:\>=50% reduction of serum M-protein \& decrease in 24h urinary M-protein by \>=90%/\<200mg/24h, if present at baseline,\>=50% decrease in SPD of soft tissue plasmacytoma.
| percentage of participants | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Percentage of Participants With Overall Response (OR) as Determined by Independent Response Committee: Primary Analysis | 82.9 | 86.6 |
VGPR or better: defined as participants with sCR, CR and VGPR as the best overall response (defined as best response from start of treatment until disease progression, death, initiation of further anti-myeloma treatment or cut-off date whichever occurs first) as per IRC. As per IMWG response criteria: sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in BMAs plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in BMAs. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein plus urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma.
| percentage of participants | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Percentage of Participants With Very Good Partial Response (VGPR) or Better as Determined by Independent Response Committee: Primary Analysis | 56.1 | 72.6 |
Percentage of participants with sCR, CR and VGPR for whom MRD assessed by sequencing was negative at any time after first dose of study treatment. MRD was assessed centrally by next-generation sequencing in bone marrow aspiration samples from participants who achieve VGPR or better, to determine depth of response at molecular level. VGPR or better: percentage of participants with sCR, CR and VGPR. sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in BMAs plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in BMAs. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein plus urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma.
| percentage of participants | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Percentage of Participants With VGPR or Better With Minimal Residual Disease (MRD) Negativity: Primary Analysis | 13.0 | 29.6 |
Percentage of participants with sCR, CR and VGPR for whom MRD assessed by sequencing was negative at any time after first dose of study treatment. MRD was assessed centrally by next-generation sequencing in BM aspiration samples from participants who achieve VGPR or better, to determine depth of response at molecular level. VGPR or better: percentage of participants with sCR, CR and VGPR. sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates plus normal FLC ratio, absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein plus urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma.
| percentage of participants | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Percentage of Participants With VGPR or Better With Minimal Residual Disease (MRD) Negativity: Final Analysis | 13.8 | 33.5 |
Complete response was defined as the participants with sCR and CR. IMWG response criteria for sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates plus normal free light chain (FLC) ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates. Complete response at the time of the final analysis was assessed with hydrashift isatuximab immunofixation electrophoresis (IFE) assay, which separated immunoglobulin G (IgG) isatuximab from IgG M protein.
| percentage of participants | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Percentage of Participants With Complete Response (CR) as Per Independent Response Committee: Final Analysis | 28.5 | 44.1 |
MRD negativity was defined as the percentage of participants for whom MRD was negative by next-generation sequencing at any timepoint after first dose of study treatment. Threshold for negativity is 10\^-5. MRD status in a participant was negative if at least one result of the assessment was negative in the participant otherwise MRD was considered as positive (MRD status reported as positive, missing or unevaluable). CR: participants with sCR and CR. IMWG response criteria for sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates. Complete response at the time of the final analysis was assessed with Hydrashift isatuximab IFE assay, which separated IgG isatuximab from IgG M protein.
| percentage of participants | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Percentage of Participants With Complete Response With MRD Negativity: Final Analysis | 12.2 | 26.3 |
Overall survival, defined as the time from the date of randomization to death from any cause. The data reported is based on cut-off date of 7 Feb 2023.
| months | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Overall Survival (OS) | 50.60 (38.932 to NA) | NA (52.172 to NA) |
DOR: time (in months) from date of 1st IRC determined response for participants achieving PR/better to date of 1st documented PD determined by IRC/death, whichever happens 1st. If disease progression/death before analysis cut-off date was not observed, DOR was censored at date of last valid disease assessment performed prior to initiation of further anti-myeloma treatment/data cut-off date, whichever was 1st. PD (IMWG criteria): inc of \>=25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute inc must be \>=0.5 g/dL), serum M-protein inc \>=1g/dL if lowest M component was \>=5g/dL; urine M-component (absolute inc must be \>=200mg/24 hour),appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>=50% inc in the longest diameter of previous lesion \>1 cm in short axis. PR: \>=50% reduction of serum M-protein \& reduction in 24h urinary M-protein by \>=90%/\<200mg/24 h. Estimated by Kaplan Meier method.
| months | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Duration of Response (DOR): Primary Analysis | NA (14.752 to NA) | NA (NA to NA) |
TTP was defined as time in months from randomization to the date of first documentation of PD (as determined by the IRC). If progression was not observed before the analysis cut-off date or the date of initiation of further anti-myeloma treatment, TTP was censored at the date of the last valid disease assessment not showing disease progression performed prior to initiation of a further anti-myeloma treatment (if any) or the analysis cut-off date, whichever comes first. As per IMWG criteria, PD was defined for participants with inc of \>= 25% from lowest confirmed value in any one of the following criteria: serum M-protein (the absolute inc must be \>= 0.5 g/dL), serum M-protein inc \>=1 g/dL if the lowest M component was \>=5 g/dL; urine M-component (the absolute inc must be \>=200 mg/24hour), appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>=50% inc in the longest diameter of a previous lesion \>1 centimeter in short axis.
| months | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Time to Progression (TTP): Primary Analysis | 20.27 (16.986 to NA) | NA (NA to NA) |
Time to first response was defined as the time (in months) from randomization to the date of first IRC determined response (PR or better) that is subsequently confirmed. In the absence of response, participants were censored at the earliest of the date of the last valid disease assessment before disease progression or death, the date of the last valid disease assessment before initiation of a further anti-myeloma treatment (if any) or the analysis cut-off date, whichever comes first. PR per IMWG criteria was defined as \>=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>=90% or to \<200 mg/24 h. In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required.
| months | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Time to First Response: Primary Analysis | 1.12 (1.051 to 1.183) | 1.08 (1.051 to 1.117) |
Time to best response was defined as time (in months) from randomization to the date of first occurrence of IRC determined as best overall response (PR or better) that is subsequently confirmed. In absence of response, participants were censored at earliest date of last valid disease assessment before disease progression/death, date of last valid disease assessment before initiation of further anti-myeloma treatment (if any)/ analysis cut-off date, whichever was 1st. PR (IMWG criteria) was defined as \>=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>=90% or to \<200 mg/24 h. In addition to above listed criteria, if present at baseline, a \>=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required. Best Overall Response was defined as the best response, using the IRC's assessment of response, from start of treatment until disease progression, death, initiation of further anti-myeloma treatment or cut-off date, whichever occurs 1st.
| months | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Time to Best Response: Primary Analysis | 3.78 (2.858 to 4.172) | 4.60 (3.811 to 5.257) |
PFS2 defined as time (in months) from date of randomization to date of 1st documentation of PD (as assessed by investigator) after initiation of further anti-myeloma treatment /death from any cause, whichever comes 1st. Participants alive without progression after initiation of further anti-myeloma treatment before analysis cut-off date, PFS2 censored at date of last follow-up visit not showing disease progression after initiation of further anti-myeloma treatment /analysis cut-off date, whichever comes 1st. As per IMWG criteria, PD: defined for participants with increase of \>= 25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute increase must be \>= 0.5 g/dL), serum M-protein increase \>=1 g/dL if lowest M component was \>=5 g/dL; urine M-component (absolute increase must be \>=200 mg/24hour), appearance of new lesion(s), \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter short axis.
| months | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Second Progression Free Survival (PFS2): Final Analysis - Data Cut-off Date of 14 Jan 2022 | 35.58 (24.049 to 40.509) | 47.18 (38.111 to NA) |
PFS2 defined as time (in months) from date of randomization to date of 1st documentation of PD (as assessed by investigator) after initiation of further anti-myeloma treatment /death from any cause, whichever comes 1st. Participants alive without progression after initiation of further anti-myeloma treatment before analysis cut-off date, PFS2 censored at date of last follow-up visit not showing disease progression after initiation of further anti-myeloma treatment /analysis cut-off date, whichever comes 1st. As per IMWG criteria, PD: defined for participants with increase of \>= 25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute increase must be \>= 0.5 g/dL), serum M-protein increase \>=1 g/dL if lowest M component was \>=5 g/dL; urine M-component (absolute increase must be \>=200 mg/24hour), appearance of new lesion(s), \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter short axis.
| months | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Second Progression Free Survival (PFS2): Overal Survival Analysis - Data Cut-off Date of 07 Feb 2023 | 32.36 (23.129 to 40.016) | 47.18 (38.965 to 57.922) |
RR comprises of complete RR (CR renal), partial RR (PR renal) \& minor RR (MR renal). CR renal was defined as an improvement in estimated glomerular filtration rate (eGFR) from \<50 mL/min/1.73m\^2 at Baseline to \>=60 mL/min/1.73m\^2 in at least 1 assessment during the treatment period (time from first dose of study treatment up to 30 days after last dose of study treatment); PR renal was defined as improvement in eGFR from \<15 mL/min/1.73m\^2 at baseline to at least 1 assessment in the range of 30 to 60 mL/min/1.73m\^2 during the on-treatment-period and MR renal was defined as an improvement in eGFR from \<15 mL/min/1.73m\^2 at Baseline to at least 1 assessment in the range of 15 to 30 mL/min/1.73m\^2 during the on-treatment-period or from 15 to 30 mL/min/1.73m\^2 at Baseline to at least 1 assessment in the range of 30 to 60 mL/min/1.73m\^2 during the on-treatment-period.
| Participants | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| CR Renal | 4 | 13 |
| MR Renal | 1 | 4 |
EORTC QLQ-C30 is a cancer-specific instrument that contains 30 items \& provides multidimensional assessment of HRQL. EORTC QLQ-C30 includes global health status/quality of life (GHS/QOL), functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 are 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale \& are 7-point scale (1/Very Poor to 7/Excellent). GHS total score is calculated as (\[{Q29+Q30}/2\]-1)/6\*100. Answers are converted into grading scale, with values between 0 (worse outcome) to100 (best outcome). High score represents a favorable outcome with best quality of life for participant. Results reported for primary analysis with data cut-off date 7-Feb-2020.
| score on a scale | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Cycle 2 Day 1 | 1.52 ± 21.11 | -1.60 ± 20.06 |
| Cycle 3 Day 1 | 4.17 ± 22.92 | 0.05 ± 20.29 |
| Cycle 4 Day 1 | 3.58 ± 21.20 | -1.89 ± 23.71 |
| Cycle 5 Day 1 | 3.60 ± 21.80 | -1.23 ± 23.12 |
| Cycle 6 Day 1 | 3.13 ± 20.50 | -1.44 ± 22.12 |
| Cycle 7 Day 1 | 4.22 ± 22.55 | -1.77 ± 22.38 |
| Cycle 8 Day 1 | 3.82 ± 21.71 | -1.06 ± 20.78 |
| Cycle 9 Day 1 | 6.60 ± 19.28 | -0.78 ± 22.17 |
| Cycle 10 Day 1 | 4.91 ± 21.55 | -1.21 ± 20.35 |
| Cycle 11 Day 1 | 4.34 ± 20.06 | -1.10 ± 20.18 |
| Cycle 12 Day 1 | 8.59 ± 22.37 | 0.84 ± 22.40 |
| Cycle 13 Day 1 | 7.08 ± 19.76 | -1.26 ± 20.63 |
| Cycle 14 Day 1 | 9.75 ± 21.62 | -0.98 ± 21.43 |
| Cycle 15 Day 1 | 5.26 ± 22.14 | 0.16 ± 20.51 |
| Cycle 16 Day 1 | 6.33 ± 20.73 | -1.07 ± 20.94 |
| Cycle 17 Day 1 | 7.27 ± 21.04 | 0.00 ± 22.18 |
| Cycle 18 Day 1 | 8.70 ± 23.16 | -0.36 ± 20.56 |
| Cycle 19 Day 1 | 12.40 ± 21.42 | -1.23 ± 20.12 |
| Cycle 20 Day 1 | 10.78 ± 20.97 | -1.05 ± 20.40 |
| Cycle 21 Day 1 | 12.50 ± 21.81 | -1.85 ± 21.54 |
| Cycle 22 Day 1 | 17.98 ± 22.27 | 0.31 ± 21.24 |
| Cycle 23 Day 1 | 15.56 ± 22.02 | 3.15 ± 20.73 |
| Cycle 24 Day 1 | 14.81 ± 26.28 | 0.38 ± 14.88 |
| Cycle 25 Day 1 | 15.00 ± 28.50 | 3.13 ± 17.18 |
| End of Treatment | -6.14 ± 22.90 | -11.90 ± 25.86 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. Disease symptoms domain is one of the four domain scores. Disease symptoms domain consist of 6 questions and the score uses 4-point scale (1 'Not at All' to 4 'Very Much'). Disease Symptoms Domain Score is calculated as (\[{Q31+Q32+Q33+Q34+Q35+Q36}/6\]-1)/3\*100. Scores are averaged, and transformed to 0-100 scale, where higher scores = more symptoms and lower HRQL.
| score on a scale | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Cycle 2 Day 1 | -5.34 ± 15.75 | -3.40 ± 19.58 |
| Cycle 3 Day 1 | -8.28 ± 15.33 | -7.42 ± 18.15 |
| Cycle 4 Day 1 | -5.45 ± 17.48 | -7.46 ± 17.99 |
| Cycle 5 Day 1 | -5.78 ± 17.01 | -6.37 ± 18.32 |
| Cycle 6 Day 1 | -6.11 ± 18.07 | -6.16 ± 19.88 |
| Cycle 7 Day 1 | -6.64 ± 17.44 | -4.78 ± 20.77 |
| Cycle 8 Day 1 | -6.94 ± 17.76 | -5.47 ± 19.96 |
| Cycle 9 Day 1 | -5.65 ± 18.00 | -5.51 ± 17.86 |
| Cycle 10 Day 1 | -5.56 ± 18.48 | -4.98 ± 17.24 |
| Cycle 11 Day 1 | -3.24 ± 17.78 | -7.10 ± 17.57 |
| Cycle 12 Day 1 | -5.30 ± 16.27 | -6.89 ± 17.58 |
| Cycle 13 Day 1 | -7.69 ± 17.06 | -5.95 ± 16.44 |
| Cycle 14 Day 1 | -8.66 ± 16.35 | -7.08 ± 17.98 |
| Cycle 15 Day 1 | -5.56 ± 17.69 | -5.19 ± 17.84 |
| Cycle 16 Day 1 | -8.06 ± 18.27 | -5.77 ± 18.66 |
| Cycle 17 Day 1 | -7.57 ± 19.01 | -4.29 ± 19.73 |
| Cycle 18 Day 1 | -7.16 ± 17.67 | -3.78 ± 17.93 |
| Cycle 19 Day 1 | -7.18 ± 19.57 | -3.64 ± 16.70 |
| Cycle 20 Day 1 | -11.93 ± 17.09 | -3.54 ± 21.63 |
| Cycle 21 Day 1 | -9.72 ± 16.74 | -3.81 ± 19.70 |
| Cycle 22 Day 1 | -9.94 ± 18.76 | -5.35 ± 22.48 |
| Cycle 23 Day 1 | -5.56 ± 25.11 | -6.01 ± 19.53 |
| Cycle 24 Day 1 | -6.17 ± 29.97 | -9.60 ± 18.16 |
| Cycle 25 Day 1 | -12.22 ± 28.97 | -14.58 ± 21.65 |
| End of Treatment | 2.35 ± 23.10 | 1.75 ± 23.48 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. Side effects of treatment domain is one of the four domain scores. Side effects of treatment domain consists of 10 questions and the score uses a 4-point scale (1 'Not at All' to 4 'Very Much'). Side Effects of Treatment Score (MYSE) is calculated as (\[{Q37+Q38+Q39+Q40+Q41+Q42+Q43+Q44+Q45+Q46}/10\]-1)/3\*100. Scores are averaged, and transformed to 0-100 scale, where higher scores = more side effects and lower HRQL and lower scores = less side effects and better HRQL.
| score on a scale | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Cycle 2 Day 1 | 1.23 ± 11.56 | 1.41 ± 11.71 |
| Cycle 3 Day 1 | 0.44 ± 10.11 | 0.84 ± 12.00 |
| Cycle 4 Day 1 | 0.83 ± 11.38 | 0.99 ± 11.89 |
| Cycle 5 Day 1 | 1.91 ± 11.36 | 2.36 ± 11.94 |
| Cycle 6 Day 1 | 2.08 ± 11.81 | 1.61 ± 12.32 |
| Cycle 7 Day 1 | 1.47 ± 12.14 | 2.14 ± 10.76 |
| Cycle 8 Day 1 | 1.53 ± 12.07 | 2.86 ± 12.77 |
| Cycle 9 Day 1 | 1.68 ± 11.57 | 1.49 ± 11.96 |
| Cycle 10 Day 1 | 2.07 ± 11.62 | 2.68 ± 12.51 |
| Cycle 11 Day 1 | 3.38 ± 12.00 | 2.03 ± 12.16 |
| Cycle 12 Day 1 | 1.20 ± 10.52 | 3.04 ± 12.72 |
| Cycle 13 Day 1 | 0.82 ± 10.22 | 2.12 ± 12.33 |
| Cycle 14 Day 1 | 1.08 ± 10.56 | 1.71 ± 12.58 |
| Cycle 15 Day 1 | 1.85 ± 11.45 | 1.87 ± 11.80 |
| Cycle 16 Day 1 | 0.99 ± 10.54 | 2.58 ± 11.88 |
| Cycle 17 Day 1 | 2.74 ± 10.03 | 4.10 ± 12.77 |
| Cycle 18 Day 1 | 2.37 ± 10.51 | 2.95 ± 13.38 |
| Cycle 19 Day 1 | 2.76 ± 11.41 | 2.16 ± 11.56 |
| Cycle 20 Day 1 | -0.17 ± 10.62 | 2.05 ± 13.03 |
| Cycle 21 Day 1 | 3.17 ± 10.61 | 2.74 ± 12.87 |
| Cycle 22 Day 1 | 3.55 ± 6.46 | 1.51 ± 12.51 |
| Cycle 23 Day 1 | 7.85 ± 9.93 | -1.39 ± 12.02 |
| Cycle 24 Day 1 | 12.35 ± 7.17 | -2.54 ± 11.33 |
| Cycle 25 Day 1 | 11.85 ± 4.06 | -3.50 ± 12.83 |
| End of Treatment | 4.63 ± 13.01 | 5.56 ± 16.22 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. It consists of one question and scores are based on the 4-point Likert scale ranging from "Not at all" to "Very much". Body image score is calculated as: (1 - \[Q47-1\]/3)\*100. Scores are averaged, and transformed to scale ranging from 0 to 100. A higher score represents a better quality of life.
| score on a scale | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Cycle 2 Day 1 | -1.29 ± 23.76 | -1.27 ± 21.31 |
| Cycle 3 Day 1 | 1.98 ± 23.01 | 1.27 ± 26.84 |
| Cycle 4 Day 1 | -1.65 ± 25.55 | -1.10 ± 28.04 |
| Cycle 5 Day 1 | -0.69 ± 26.34 | -2.89 ± 27.29 |
| Cycle 6 Day 1 | -1.83 ± 24.02 | -1.60 ± 26.93 |
| Cycle 7 Day 1 | -0.77 ± 27.83 | -3.03 ± 24.36 |
| Cycle 8 Day 1 | -5.16 ± 25.08 | -0.25 ± 24.84 |
| Cycle 9 Day 1 | -2.14 ± 24.82 | -1.02 ± 25.80 |
| Cycle 10 Day 1 | -1.80 ± 25.22 | -1.33 ± 25.54 |
| Cycle 11 Day 1 | -1.85 ± 29.01 | -0.55 ± 23.47 |
| Cycle 12 Day 1 | -2.05 ± 25.60 | -0.55 ± 25.09 |
| Cycle 13 Day 1 | -3.89 ± 26.10 | -2.63 ± 21.79 |
| Cycle 14 Day 1 | -4.52 ± 26.59 | -3.24 ± 25.57 |
| Cycle 15 Day 1 | 0.00 ± 25.20 | -2.22 ± 24.58 |
| Cycle 16 Day 1 | -1.31 ± 27.46 | -2.94 ± 22.55 |
| Cycle 17 Day 1 | -1.42 ± 28.62 | -1.98 ± 26.17 |
| Cycle 18 Day 1 | 1.48 ± 30.11 | -1.77 ± 24.62 |
| Cycle 19 Day 1 | 0.00 ± 31.62 | -3.70 ± 26.18 |
| Cycle 20 Day 1 | 0.00 ± 27.22 | -0.76 ± 24.75 |
| Cycle 21 Day 1 | -4.76 ± 34.80 | -3.20 ± 26.74 |
| Cycle 22 Day 1 | -8.77 ± 36.59 | -1.85 ± 27.02 |
| Cycle 23 Day 1 | -13.33 ± 30.34 | -5.41 ± 24.23 |
| Cycle 24 Day 1 | -25.93 ± 36.43 | -3.03 ± 25.01 |
| Cycle 25 Day 1 | -53.33 ± 18.26 | -8.33 ± 25.82 |
| End of Treatment | -5.65 ± 21.58 | -9.36 ± 27.28 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. It consists of three questions and the scores are based on the 4-point Likert scale ranging from "Not at all" to "Very much". Future Perspective score is calculated as (1 - (\[{Q48+Q49+Q50}/3\] -1)/3)\*100. Scores are averaged and transformed to scale ranging from 0 to 100. A higher score represents a better quality of life.
| score on a scale | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Cycle 2 Day 1 | 0.54 ± 19.33 | 7.57 ± 26.48 |
| Cycle 3 Day 1 | 4.84 ± 22.08 | 9.70 ± 24.76 |
| Cycle 4 Day 1 | 6.60 ± 20.44 | 8.55 ± 26.62 |
| Cycle 5 Day 1 | 7.67 ± 22.64 | 7.56 ± 26.98 |
| Cycle 6 Day 1 | 8.42 ± 21.81 | 9.97 ± 25.70 |
| Cycle 7 Day 1 | 8.17 ± 21.93 | 8.47 ± 24.74 |
| Cycle 8 Day 1 | 7.41 ± 22.51 | 10.54 ± 24.50 |
| Cycle 9 Day 1 | 7.26 ± 21.10 | 8.57 ± 28.26 |
| Cycle 10 Day 1 | 8.56 ± 22.79 | 11.56 ± 24.82 |
| Cycle 11 Day 1 | 8.02 ± 21.69 | 12.02 ± 24.23 |
| Cycle 12 Day 1 | 6.84 ± 24.51 | 11.48 ± 22.90 |
| Cycle 13 Day 1 | 11.11 ± 20.04 | 10.72 ± 23.18 |
| Cycle 14 Day 1 | 8.85 ± 22.86 | 11.31 ± 23.29 |
| Cycle 15 Day 1 | 9.55 ± 24.16 | 12.28 ± 22.27 |
| Cycle 16 Day 1 | 12.42 ± 24.51 | 11.76 ± 25.20 |
| Cycle 17 Day 1 | 12.29 ± 21.64 | 10.89 ± 25.29 |
| Cycle 18 Day 1 | 11.36 ± 22.41 | 7.33 ± 23.25 |
| Cycle 19 Day 1 | 9.21 ± 24.96 | 8.40 ± 25.50 |
| Cycle 20 Day 1 | 10.13 ± 24.67 | 9.60 ± 25.34 |
| Cycle 21 Day 1 | 10.32 ± 22.41 | 10.65 ± 26.15 |
| Cycle 22 Day 1 | 8.77 ± 25.28 | 12.14 ± 22.35 |
| Cycle 23 Day 1 | 9.63 ± 27.81 | 12.61 ± 20.48 |
| Cycle 24 Day 1 | 1.23 ± 24.50 | 16.16 ± 18.70 |
| Cycle 25 Day 1 | -4.44 ± 24.34 | 15.28 ± 16.67 |
| End of Treatment | -3.95 ± 22.86 | -3.70 ± 31.45 |
The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health utility and consist in 2 sections a descriptive system comprising 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and Visual Analog Scale (VAS). Each dimension has a 5-level response: no problems, slight problems, moderate problems, severe problems, and extreme problems. Response options are measured with a 5-point Likert scale. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state and lower score indicate worse health state.
| score on a scale | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Cycle 2 Day 1 | 0.05 ± 0.17 | 0.04 ± 0.19 |
| Cycle 3 Day 1 | 0.06 ± 0.21 | 0.05 ± 0.22 |
| Cycle 4 Day 1 | 0.02 ± 0.21 | 0.05 ± 0.21 |
| Cycle 5 Day 1 | 0.04 ± 0.20 | 0.04 ± 0.20 |
| Cycle 6 Day 1 | 0.03 ± 0.19 | 0.05 ± 0.23 |
| Cycle 7 Day 1 | 0.06 ± 0.19 | 0.04 ± 0.21 |
| Cycle 8 Day 1 | 0.06 ± 0.19 | 0.05 ± 0.22 |
| Cycle 9 Day 1 | 0.05 ± 0.20 | 0.04 ± 0.19 |
| Cycle 10 Day 1 | 0.06 ± 0.22 | 0.03 ± 0.22 |
| Cycle 11 Day 1 | 0.04 ± 0.23 | 0.05 ± 0.20 |
| Cycle 12 Day 1 | 0.03 ± 0.16 | 0.02 ± 0.20 |
| Cycle 13 Day 1 | 0.06 ± 0.16 | 0.03 ± 0.19 |
| Cycle 14 Day 1 | 0.06 ± 0.24 | 0.04 ± 0.19 |
| Cycle 15 Day 1 | 0.05 ± 0.18 | 0.05 ± 0.18 |
| Cycle 16 Day 1 | 0.06 ± 0.16 | 0.04 ± 0.19 |
| Cycle 17 Day 1 | 0.05 ± 0.15 | 0.03 ± 0.20 |
| Cycle 18 Day 1 | 0.02 ± 0.15 | 0.04 ± 0.17 |
| Cycle 19 Day 1 | 0.03 ± 0.20 | 0.03 ± 0.18 |
| Cycle 20 Day 1 | 0.06 ± 0.17 | 0.03 ± 0.23 |
| Cycle 21 Day 1 | 0.03 ± 0.15 | 0.02 ± 0.22 |
| Cycle 22 Day 1 | 0.05 ± 0.19 | 0.02 ± 0.22 |
| Cycle 23 Day 1 | 0.05 ± 0.18 | 0.00 ± 0.27 |
| Cycle 24 Day 1 | 0.04 ± 0.24 | 0.03 ± 0.20 |
| Cycle 25 Day 1 | 0.05 ± 0.38 | 0.04 ± 0.22 |
| End of Treatment | -0.03 ± 0.25 | -0.08 ± 0.27 |
The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health utility and consist of 2 sections; descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a VAS. The VAS records the respondent's self-rated health on a 20 centimeter (cm) vertical VAS; the scale went from 0 (worst imaginable health state) to 100 (best imaginable health state). This information can be used as a quantitative measure of health as judged by the individual respondents.
| score on a scale | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Cycle 2 Day 1 | 2.42 ± 17.04 | 0.60 ± 15.23 |
| Cycle 3 Day 1 | 4.70 ± 16.13 | 3.47 ± 17.80 |
| Cycle 4 Day 1 | 6.03 ± 16.73 | 2.29 ± 18.69 |
| Cycle 5 Day 1 | 3.40 ± 16.89 | 2.35 ± 19.73 |
| Cycle 6 Day 1 | 2.80 ± 18.56 | 1.24 ± 19.11 |
| Cycle 7 Day 1 | 0.64 ± 21.69 | 2.24 ± 18.85 |
| Cycle 8 Day 1 | 1.48 ± 17.11 | 2.40 ± 18.87 |
| Cycle 9 Day 1 | -0.14 ± 17.46 | 2.93 ± 19.04 |
| Cycle 10 Day 1 | 2.76 ± 17.41 | 2.82 ± 18.35 |
| Cycle 11 Day 1 | 3.86 ± 20.07 | 3.77 ± 18.51 |
| Cycle 12 Day 1 | 5.29 ± 18.51 | 3.63 ± 19.34 |
| Cycle 13 Day 1 | 6.81 ± 19.57 | 4.94 ± 18.41 |
| Cycle 14 Day 1 | 7.95 ± 18.12 | 4.72 ± 17.67 |
| Cycle 15 Day 1 | 4.96 ± 18.92 | 3.23 ± 18.87 |
| Cycle 16 Day 1 | 3.94 ± 18.78 | 4.56 ± 18.88 |
| Cycle 17 Day 1 | 5.04 ± 17.93 | 4.97 ± 18.55 |
| Cycle 18 Day 1 | 3.71 ± 19.08 | 3.83 ± 18.46 |
| Cycle 19 Day 1 | 7.44 ± 18.73 | 3.69 ± 18.37 |
| Cycle 20 Day 1 | 6.18 ± 18.43 | 4.20 ± 17.20 |
| Cycle 21 Day 1 | 7.25 ± 23.46 | 3.26 ± 18.97 |
| Cycle 22 Day 1 | 5.58 ± 24.06 | 2.35 ± 18.62 |
| Cycle 23 Day 1 | 6.33 ± 18.73 | 6.44 ± 18.34 |
| Cycle 24 Day 1 | 5.11 ± 17.93 | 4.50 ± 18.31 |
| Cycle 25 Day 1 | 9.20 ± 21.48 | 5.00 ± 18.83 |
| End of Treatment | -4.40 ± 18.66 | -7.80 ± 21.08 |
Ceoi is the plasma concentration observed at the end of intravenous infusion.
| microgram/milliliter (mcg/mL) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|
| Cycle 1 Day 1 | 274.01 ± 183.67 |
| Cycle 1 Day 15 | 380.28 ± 85.70 |
| Cycle 2 Day 1 | 522.74 ± 204.11 |
Ctrough was the plasma concentration observed just before treatment administration during repeated dosing.
| mcg/mL | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|
| Cycle 1 Day 1 | 3.66 ± 34.40 |
| Cycle 1 Day 8 | 82.14 ± 43.87 |
| Cycle 1 Day 15 | 180.02 ± 71.83 |
| Cycle 1 Day 22 | 252.63 ± 100.16 |
| Cycle 2 Day 1 | 324.28 ± 132.98 |
| Cycle 3 Day 1 | 295.78 ± 146.11 |
| Cycle 4 Day 1 | 342.48 ± 140.94 |
| Cycle 5 Day 1 | 389.25 ± 172.11 |
| Cycle 6 Day 1 | 427.16 ± 188.51 |
| Cycle 7 Day 1 | 433.22 ± 177.11 |
| Cycle 8 Day 1 | 490.51 ± 198.17 |
| Cycle 9 Day 1 | 486.07 ± 181.34 |
| Cycle 10 Day 1 | 490.08 ± 206.53 |
Cmax was defined as the maximum concentration observed after the first infusion calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
| nanogram/milliliter (ng/mL) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|
| Pharmacokinetics: Maximum Observed Concentration (Cmax) of Carfilzomib: Primary Analysis | 2090 ± 1360 |
Clast was defined as the last concentration observed above the lower limit of quantification.
| ng/mL | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|
| Pharmacokinetics: Clast of Carfilzomib: Primary Analysis | 3.00 ± 5.11 |
Tmax was defined as the time to reach Cmax, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
| hours | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|
| Pharmacokinetics: Tmax of Carfilzomib: Primary Analysis | 0.54 (0.35 to 0.75) |
Tlast was defined as the time of last concentration observed above the lower limit of quantification, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
| hours | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|
| Pharmacokinetics: Tlast of Carfilzomib: Primary Analysis | 4.50 (2.52 to 4.75) |
AUC was defined as area under the plasma concentration-time curve extrapolated to infinity according to the equation: AUC= AUClast + Clast/λz. AUC was calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
| nanograms*hour/milliliter(ng*h/mL) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|
| Pharmacokinetics: Area Under the Plasma Concentration Time Curve (AUC) of Carfilzomib: Primary Analysis | 784 ± 509 |
AUClast was defined as area under the plasma concentration versus time curve calculated from time 0 to last quantifiable concentration. AUClast was calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
| ng*h/mL | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|
| Pharmacokinetics: Area Under the Plasma Concentration Time Curve From Time 0 to Last Quantifiable Concentration (AUClast) of Carfilzomib: Primary Analysis | 779 ± 505 |
AUCext was defined as the percentage of the extrapolation of AUC, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
| percentage of AUC | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|
| Pharmacokinetics: Percentage of Extrapolation of AUC (AUCext) of Carfilzomib: Primary Analysis | 0 ± 172 |
T1/2 was defined as the time required for the concentration of the drug to reach half of its original value, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
| hours | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|
| Pharmacokinetics: Terminal Half-life (t1/2z) of Carfilzomib: Primary Analysis | 0.860 (0.450 to 1.89) |
CLss was defined as a quantitative measure of the rate at which a drug substance is removed from the body at steady state, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
| Liters/hour (L/h) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|
| Pharmacokinetics: Clearance at Steady State (CLss) of Carfilzomib: Primary Analysis | 466 ± 1190 |
Volume of Distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss is the apparent volume of distribution at steady-state, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab.
| Liters | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|
| Pharmacokinetics: Volume of Distribution at Steady State (Vss) of Carfilzomib: Primary Analysis | 453 ± 1570 |
ADA were categorized as: pre-existing, treatment induced, and treatment boosted response. Pre-existing ADA was defined as ADA that were present in samples drawn during the pretreatment period (i.e., before the first isatuximab administration). Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA, including participants without pretreatment samples. Treatment boosted ADA was defined as pre-existing ADA with an increase in titer during the ADA on-study observation period.
| Participants | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|
| Pre-existing ADA | 0 |
| Treatment induced ADA | 0 |
| Treatment boosted ADA | 0 |
Adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAEs were defined as AEs that developed, worsened, or became serious during the treatment period (time from the first dose of study treatments up to 30 days after last dose of study treatments). An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability / incapacity, was a congenital anomaly/birth defect, was a medically important event.
| Participants | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Any TEAE | 119 | 175 |
| Any treatment emergent SAE | 74 | 129 |
Time (in months) from randomization to date of 1st documentation of progressive disease (PD)/date of death from any cause, whichever comes 1st. If PD \& death are not observed before cut-off date/date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment not showing PD performed prior to initiation of further anti-myeloma treatment/cut-off date, whichever comes 1st. PD(IMWG criteria):any 1 of following:Increase(inc) of \>=25% in serum M-component from nadir; serum M component inc \>=1 g/dL in 2 consecutive assessment, if starting M component \>=5 g/dL; and/or inc of \>=25% in urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc \>=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion if \>1 lesion/ \>=50% increase in longest diameter of previous soft tissue extramedullary disease lesion \>1 cm in short axis. Estimated by Kaplan-Meier method.
| months | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Progression Free Survival (PFS) As Determined by Independent Response Committee (IRC): Primary Analysis | 19.15 (15.770 to NA) | NA (NA to NA) |
Time (in months) from randomization to date of 1st PD documentation/death date, whichever is 1st. If PD \& death not observed before cut-off date/date of further anti-myeloma treatment initiation, PFS censored at date of last valid disease assessment not showing PD performed prior to initiation of further anti-myeloma treatment/cut-off date, whichever was 1st. Progression/deaths occurring \>8 weeks after last disease assessment censored at earliest date of last disease assessment without evidence of progression before initiation of new anti-myeloma treatment \& cut-off date. PD (IMWG criteria): meeting any 1: Inc \>=25% in Serum M-component from nadir; serum M component inc \>=1 g/dL in 2 consecutive assessment, if starting M component \>=5 g/dL; and/or inc \>=25% in Urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc \>=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion \>1 cm short axis.
| months | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Progression Free Survival as Determined by Independent Response Committee: [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Primary Analysis | 20.27 (15.770 to NA) | NA (NA to NA) |
PFS: time (in months) from randomization to date of first documentation of PD or date of death from any cause, whichever comes first. If PD and death are not observed before analysis cut-off date or date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment or analysis cut-off date, whichever comes first. PD as per IMWG criteria: any 1 of following: Inc of \>=25% in Serum M-component from nadir; serum M component increase \>=1 g/dL in 2 consecutive assessment, if starting M component was \>=5 g/dL; and/or inc of \>=25% in Urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc \>=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion if \>1 lesion/ \>=50% inc in longest diameter of previous soft tissue extramedullary disease lesion \>1 cm in short axis. PFS estimated by Kaplan-Meier method.
| months | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Progression Free Survival as Determined by Independent Response Committee: Final Analysis | 19.15 (15.770 to 25.035) | 35.65 (25.758 to 43.959) |
Time (in months) from randomization to date of 1st documentation of PD/date of death from any cause, whichever comes 1st. If PD \& death are not observed before cut-off date/date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment not showing PD/cut-off date, whichever comes 1st. Progressions/deaths occurring \>8 weeks after last disease assessment were censored at earliest date of last valid disease assessment not showing PD before initiation of further anti-myeloma treatment \& cut-off date. PD (per IMWG criteria): meeting any 1 criteria: Inc of \>=25% in serum M-component from nadir; serum M component inc \>=1 g/dL in 2 consecutive assessment, if starting M component was \>=5 g/dL; and/or inc of \>=25% in urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc \>=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion \>1 cm in short axis.
| months | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Progression Free Survival as Determined by Independent Response Committee [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Final Analysis | 20.76 (16.164 to 28.189) | 41.66 (27.138 to NA) |
Collected over AE data and deaths were collected during the whole study. TEAEs that developed, worsened, or became serious during the treatment period were assessed from first dose of study treatment administration (Day 1) up to 30 days post last dose of study treatment administration, up to 349 weeks for Kd arm and 356 weeks for IKd arm (maximum duration of treatment exposure).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Carfilzomib + Dexamethasone (Kd) | 59/123 (48%) | 74/122 (60.7%) | 113/122 (92.6%) |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 83/179 (46.4%) | 129/177 (72.9%) | 167/177 (94.4%) |
| Event | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| PneumoniaInfections and infestations | 17/122 | 41/177 |
| Lower Respiratory Tract InfectionInfections and infestations | 6/122 | 8/177 |
| InfluenzaInfections and infestations | 5/122 | 2/177 |
| Acute Kidney InjuryRenal and urinary disorders | 5/122 | 3/177 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/122 | 6/177 |
| Cardiac FailureCardiac disorders | 4/122 | 5/177 |
| Deep Vein ThrombosisVascular disorders | 4/122 | 3/177 |
| Covid-19Infections and infestations | 1/122 | 5/177 |
| Pathological FractureMusculoskeletal and connective tissue disorders | 1/122 | 5/177 |
| Traumatic FractureInjury, poisoning and procedural complications | 2/122 | 5/177 |
| Event | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) |
|---|---|---|
| Infusion Related ReactionInjury, poisoning and procedural complications | 4/122 | 80/177 |
| Upper Respiratory Tract InfectionInfections and infestations | 32/122 | 73/177 |
| DiarrhoeaGastrointestinal disorders | 38/122 | 72/177 |
| HypertensionVascular disorders | 42/122 | 69/177 |
| FatigueGeneral disorders | 25/122 | 57/177 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 28/122 | 54/177 |
| InsomniaPsychiatric disorders | 30/122 | 46/177 |
| BronchitisInfections and infestations | 14/122 | 43/177 |
| Back PainMusculoskeletal and connective tissue disorders | 25/122 | 43/177 |
| CoughRespiratory, thoracic and mediastinal disorders | 18/122 | 41/177 |
Analysis was performed on randomized population.
| Age, Continuous(years) | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) | Total |
|---|---|---|---|
| Mean | 62.9 ± 10.0 | 63.3 ± 9.8 | 63.1 ± 9.9 |
| Sex: Female, Male(Participants) | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) | Total |
|---|---|---|---|
| Female | 55 | 78 | 133 |
| Male | 68 | 101 | 169 |
| Race (NIH/OMB)(Participants) | Carfilzomib + Dexamethasone (Kd) | Isatuximab + Carfilzomib + Dexamethasone (IKd) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 24 | 26 | 50 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 5 | 9 |
| White | 83 | 131 | 214 |
| More than one race | 0 | 3 | 3 |
| Unknown or Not Reported | 12 | 14 | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Oct 2017 to primary completion in Jan 2022, 50 months.
Results were first posted in Feb 2023, 1 year after primary completion.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 50 months is above that.
Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.